Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists.

导出 OA

翻译打印收藏纠错

第一作者： Stefan,Peukert

第一单位： Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

作者： Stefan,Peukert ^[1] ; Richard,Hughes ^[1] ; Jill,Nunez ^[1] ; Guo,He ^[1] ; Zhao,Yan ^[1] ; Rishi,Jain ^[1] ; Luis,Llamas ^[1] ; Sarah,Luchansky ^[1] ; Adam,Carlson ^[1] ; Guiqing,Liang ^[1] ; Vidya,Kunjathoor ^[1] ; Mike,Pietropaolo ^[1] ; Jeffrey,Shapiro ^[1] ; Anja,Castellana ^[1] ; Xiaoping,Wu ^[1] ; Avirup,Bose ^[1]

作者单位： Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States. ^[1]

关键词 GLP-1 secretion GPR39 agonists GPR39 receptor Zn2+-sensing receptor antidiabetic treatment insulin secretion β-cell protection

DOI 10.1021/ml500240d

PMID 25313322

发布时间 2021-10-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交